Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 833.

https://doi.org/10.1182/blood.V130.Suppl_1.833.833

Published: 2017

Journal Articles

Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model

Erik Slinger, PhD, Sriram Balasubramanian, PhD, Joel D. Leverson, PhD, Eric Eldering, Arnon P. Kater, MD

Blood (2017) 130 (Supplement 1): 3018.

https://doi.org/10.1182/blood.V130.Suppl_1.3018.3018

Published: 2017

Journal Articles

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Ajay K. Gopal, MD, Stephen J. Schuster, MD, Nathan Fowler, MD, Judith Trotman, MBChB, Georg Hess, MD, Jing-Zhou Hou, Abdulraheem Yacoub, MD, Michael Lill, MD BS, Peter Martin, MD, Umberto Vitolo, MD, Wojciech Jurczak, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, Dzhelil Osmanov, MD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Shean-sheng Wang, PhD, Sanjay Deshpande, MD, Gilles A. Salles

Blood (2016) 128 (22): 1217.

https://doi.org/10.1182/blood.V128.22.1217.1217

Published: 2016

Journal Articles

Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial

Rajendra Damle, PhD, Michael Schaffer, PhD, Shalini Chaturvedi, PhD, Charles Phelps, MSc, Regina Aquino, MSc, Michelle Mahler, MD, Mariya Salman, PhD, Angela Howes, PhD, Javier Loscertales, MD PhD, Marek Trneny, MD, Dina Ben Yehuda, MD, Alexander Pristupa, MD, Asher A. Chanan-Khan, MD, Sriram Balasubramanian, PhD

Blood (2016) 128 (22): 4397.

https://doi.org/10.1182/blood.V128.22.4397.4397

Published: 2016

Journal Articles

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Gilles A. Salles, Judith Trotman, MB ChB, Michael Lill, MD BS, Bruce Cheson, MD, Stephen J. Schuster, MD, Jing-Zhou Hou, John A Radford, MB ChB, MRCP, MD FRCP, Andrew Spencer, Michael Schaffer, PhD, Rajendra Damle, PhD, Gary J. Gartenberg, MD, Jessica Vermeulen, MD PhD, Sriram Balasubramanian, PhD, Sanjay Deshpande, MD, Dolores Caballero, MD PhD

Blood (2016) 128 (22): 2980.

https://doi.org/10.1182/blood.V128.22.2980.2980

Published: 2016

Journal Articles

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2015) 126 (23): 2938.

https://doi.org/10.1182/blood.V126.23.2938.2938

Published: 2015

Journal Articles

TP53 Mutations and Other Cell-Intrinsic Determinants of the Apoptotic Response to Ibrutinib in Chronic Lymphocytic Leukemia

Nisar A. Amin, Sriram Balasubramanian, PhD, Kamlai Saiya-Cork, Sami N. Malek

Blood (2015) 126 (23): 4165.

https://doi.org/10.1182/blood.V126.23.4165.4165

Published: 2015

Journal Articles

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Asher Chanan-Khan, MD, Paula Cramer, MD, Graeme Fraser, MDFRCPC, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Aleksander Pristupa, MD, Marie Sarah Dilhuydy, MD, Andre Goy, MD, Anthony R. Mato, MD MSCE, Rajendra Damle, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Michael Schaffer, PhD, Angela Howes, PhD, Sriram Balasubramanian, PhD

Blood (2015) 126 (23): 1732.

https://doi.org/10.1182/blood.V126.23.1732.1732

Published: 2015

Journal Articles

Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib

Leo WK Cheung, Karl J. Schweighofer, Shiquan Wu, Hsu-Ping Kuo, Karl Eckert, Sriram Balasubramanian, PhD, Deborah Ricci, Yu Liang, Darrin Beaupre, Betty Y. Chang

Blood (2015) 126 (23): 2642.

https://doi.org/10.1182/blood.V126.23.2642.2642

Published: 2015

Journal Articles

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

Blood (2015) 126 (23): 469.

https://doi.org/10.1182/blood.V126.23.469.469

Published: 2015

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

Blood (2012) 120 (21): 686.

https://doi.org/10.1182/blood.V120.21.686.686

Published: 2012

Journal Articles

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Andrew M. Evens, DO, MSc, Julie M Vose, MD, MBA, Wael Harb, MD, Leo I. Gordon, MD, Robert Langdon, MD, Barbara Grant, MD, Julian Sprague, MD, PhD, Clara Plasencia, MS, Mint Sirisawad, MS, Jeanne Yue, MS, Ying Luan, PhD, Aaron Siek, BS, Lei Zhou, MD, Sriram Balasubramanian, PhD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 55.

https://doi.org/10.1182/blood.V120.21.55.55

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways

Sriram Balasubramanian, PhD, Richard Crowley, MS, Mint Sirisawad, MS, Patti Thiemann, MS, Jun Chen, PhD, Joseph J. Buggy, PhD

Blood (2011) 118 (21): 4969.

https://doi.org/10.1182/blood.V118.21.4969.4969

Published: 2011

Journal Articles

Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,

Sabine Ponader, PhD, Sriram Balasubramanian, PhD, Lan V Pham, PhD, Jun Chen, PhD, Archito T. Tamayo, MS, Michael Wang, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Michael J Keating, MD, Richard J. Ford, MD, PhD, Jan A. Burger, MD, PhD

Blood (2011) 118 (21): 3688.

https://doi.org/10.1182/blood.V118.21.3688.3688

Published: 2011

Journal Articles

The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

Sriram Balasubramanian, PhD, Mint Sirisawad, MS, Susanne Steggerda, PhD, Wangsen Cao, MD, PhD, Charles Lowenstein, MD, Joseph J Buggy, PhD

Blood (2010) 116 (21): 3914.

https://doi.org/10.1182/blood.V116.21.3914.3914

Published: 2010

Journal Articles

Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.

Andrew M Evens, DO, MSc, Weiyun Ai, MD, PhD, Sriram Balasubramanian, PhD, Mint Sirisawad, M.S., Chitra Mani, PhD, Martha Guerra, RN, Nancy Szakacs, BS, MBA, David Loury, PhD, Joseph J Buggy, Ph.D., Ahmed Hamdy, MD, Julie M. Vose, M.D., Nancy L Bartlett, MD

Blood (2009) 114 (22): 2726.

https://doi.org/10.1182/blood.V114.22.2726.2726

Published: 2009

Journal Articles

Identification of MicroRNA Markers of Sensitivity to the Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 in Non-Hodgkin’s Lymphoma.

Sriram Balasubramanian, PhD, Jun Chen, Ph.D., Lee Honigberg, Ph.D., Lillian Tee, Hannah Mamuszka

Blood (2008) 112 (11): 3366.

https://doi.org/10.1182/blood.V112.11.3366.3366

Published: 2008

Journal Articles

The Histone Deacetylase-8 (HDAC8) Selective Inhibitor PCI-34051 Decreases Interleukin-1 Beta Secretion in Vitro and Reduces Inflammation in Vivo

Sriram Balasubramanian, PhD, Susanne Steggerda, Ph.D., Mint Sirisawad, M.S., Marshall Schreeder, Luke Doiron, Joseph J Buggy, Ph.D.

Blood (2008) 112 (11): 2581.

https://doi.org/10.1182/blood.V112.11.2581.2581

Published: 2008

Journal Articles

Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Sriram Balasubramanian, PhD, Shanthi Adimoolam, PhD, Mint Sirisawad, MS, Andrew M. Evens, DO, Leo I. Gordon, MD, Richard Miller, MD, Joseph J. Buggy, PhD

Blood (2007) 110 (11): 1377.

https://doi.org/10.1182/blood.V110.11.1377.1377

Published: 2007

Journal Articles

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Savita Bhalla, PhD, Kevin David, MD, Lauren Mauro, MD, Sheila Prachand, MS, Mint Sirisawad, Sriram Balasubramanian, PhD, Richard A. Miller, MD, Joseph Buggy, PhD, Leo I. Gordon, MD, Andrew M. Evens, DO, MS

Blood (2007) 110 (11): 3589.

https://doi.org/10.1182/blood.V110.11.3589.3589

Published: 2007

NARROW

Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Combinatorial Treatment of Chronic Lymphocytic Leukemia with Ibrutinib and Venetoclax Is Superior to Treatment with Single Agents in the TCL1 Mouse Model

Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN Study

Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial

Pseudo-Progression Among Patients with Follicular Lymphoma Treated with Ibrutinib in the Phase 2 DAWN Study

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

TP53 Mutations and Other Cell-Intrinsic Determinants of the Apoptotic Response to Ibrutinib in Chronic Lymphocytic Leukemia

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib

Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL)

The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Inhibits Growth of ABC DLBCL Tumors In Vivo and in Vitro by Preventing Activation of Pro-Survival NF-κB pathways

Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,

The Histone Deacetylase (HDAC) Inhibitor PCI-24781 Decreases Pro-Inflammatory Cytokine Secretion In Vitro and In Vivo and Protects Against Endotoxemia In a Sepsis Model

Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.

Identification of MicroRNA Markers of Sensitivity to the Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor PCI-32765 in Non-Hodgkin’s Lymphoma.

The Histone Deacetylase-8 (HDAC8) Selective Inhibitor PCI-34051 Decreases Interleukin-1 Beta Secretion in Vitro and Reduces Inflammation in Vivo

Development of RAD51 as Biomarker for Sensitivity to the Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.

Histone Deacetylase Inhibitor (HDACi) PCI-24781 and Bortezomib Result in Synergistic Apoptosis in Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL) Cell Lines: Investigation of Cell Death and NFKB-Mediated Pathways.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only